Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.05
BIIB's Cash to Debt is ranked higher than
61% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. BIIB: 2.05 )
BIIB' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: 2.05

Equity to Asset 0.73
BIIB's Equity to Asset is ranked higher than
77% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BIIB: 0.73 )
BIIB' s 10-Year Equity to Asset Range
Min: 0.54   Max: 0.87
Current: 0.73

0.54
0.87
Interest Coverage 78.86
BIIB's Interest Coverage is ranked higher than
59% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 78.86 )
BIIB' s 10-Year Interest Coverage Range
Min: 2.3   Max: 9999.99
Current: 78.86

2.3
9999.99
F-Score: 7
Z-Score: 14.87
M-Score: -2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 36.29
BIIB's Operating margin (%) is ranked higher than
97% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. BIIB: 36.29 )
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05   Max: 52.91
Current: 36.29

-128.05
52.91
Net-margin (%) 26.87
BIIB's Net-margin (%) is ranked higher than
95% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. BIIB: 26.87 )
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85   Max: 36.64
Current: 26.87

-128.85
36.64
ROE (%) 21.60
BIIB's ROE (%) is ranked higher than
96% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. BIIB: 21.60 )
BIIB' s 10-Year ROE (%) Range
Min: -12.41   Max: 30.15
Current: 21.6

-12.41
30.15
ROA (%) 15.70
BIIB's ROA (%) is ranked higher than
97% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. BIIB: 15.70 )
BIIB' s 10-Year ROA (%) Range
Min: -9.21   Max: 23.3
Current: 15.7

-9.21
23.3
ROC (Joel Greenblatt) (%) 128.46
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. BIIB: 128.46 )
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -36.67   Max: 128.46
Current: 128.46

-36.67
128.46
Revenue Growth (%) 16.30
BIIB's Revenue Growth (%) is ranked higher than
88% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. BIIB: 16.30 )
BIIB' s 10-Year Revenue Growth (%) Range
Min: -13.9   Max: 84.7
Current: 16.3

-13.9
84.7
EBITDA Growth (%) 26.20
BIIB's EBITDA Growth (%) is ranked higher than
95% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. BIIB: 26.20 )
BIIB' s 10-Year EBITDA Growth (%) Range
Min: -16.4   Max: 131
Current: 26.2

-16.4
131
EPS Growth (%) 25.60
BIIB's EPS Growth (%) is ranked higher than
93% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. BIIB: 25.60 )
BIIB' s 10-Year EPS Growth (%) Range
Min: -66   Max: 205.2
Current: 25.6

-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

BIIB Guru Trades in Q2 2013

Louis Moore Bacon 5,000 sh (New)
Ken Fisher 1,767 sh (New)
Stanley Druckenmiller 91,500 sh (New)
Ken Heebner 45,000 sh (New)
Steven Cohen 454,071 sh (+456.1%)
Frank Sands 4,565,921 sh (+27.6%)
Pioneer Investments Sold Out
Murray Stahl 8,626 sh (-3.84%)
Vanguard Health Care Fund 1,451,300 sh (-4.52%)
PRIMECAP Management 18,246,809 sh (-5%)
Jeremy Grantham 144,501 sh (-5.87%)
Jim Simons 1,393,500 sh (-13.88%)
Bill Frels 1,300 sh (-22.71%)
Andreas Halvorsen 966,288 sh (-24.91%)
Mario Gabelli 1,820 sh (-25.1%)
RS Investment Management 18,890 sh (-39.42%)
Ray Dalio 10,512 sh (-78.85%)
John Hussman 50,000 sh (-80.62%)
Paul Tudor Jones 3,800 sh (-95.08%)
» More
Q3 2013

BIIB Guru Trades in Q3 2013

Pioneer Investments 1,774 sh (New)
Louis Moore Bacon 10,000 sh (+100%)
Mario Gabelli 3,310 sh (+81.87%)
John Hussman 75,000 sh (+50%)
Frank Sands 4,635,241 sh (+1.52%)
Ken Fisher 1,774 sh (+0.4%)
Vanguard Health Care Fund 1,451,300 sh (unchged)
Stanley Druckenmiller 91,500 sh (unchged)
Ken Heebner Sold Out
Murray Stahl 8,583 sh (-0.5%)
PRIMECAP Management 17,968,172 sh (-1.53%)
RS Investment Management 18,473 sh (-2.21%)
Jeremy Grantham 136,728 sh (-5.38%)
Bill Frels 1,125 sh (-13.46%)
Jim Simons 869,700 sh (-37.59%)
Ray Dalio 6,174 sh (-41.27%)
Steven Cohen 204,605 sh (-54.94%)
Paul Tudor Jones 1,500 sh (-60.53%)
Andreas Halvorsen 290,345 sh (-69.95%)
» More
Q4 2013

BIIB Guru Trades in Q4 2013

Ray Dalio 19,057 sh (+208.67%)
Steven Cohen 260,905 sh (+27.52%)
Paul Tudor Jones 1,767 sh (+17.8%)
Ken Fisher 2,038 sh (+14.88%)
Mario Gabelli 3,710 sh (+12.08%)
RS Investment Management 19,478 sh (+5.44%)
Frank Sands 4,754,160 sh (+2.57%)
Stanley Druckenmiller 91,500 sh (unchged)
Bill Frels 1,125 sh (unchged)
Louis Moore Bacon Sold Out
Andreas Halvorsen Sold Out
John Hussman Sold Out
Jeremy Grantham 136,231 sh (-0.36%)
Murray Stahl 8,532 sh (-0.59%)
PRIMECAP Management 17,777,602 sh (-1.06%)
Pioneer Investments 1,475 sh (-16.85%)
Jim Simons 542,338 sh (-37.64%)
Vanguard Health Care Fund 884,000 sh (-39.09%)
» More
Q1 2014

BIIB Guru Trades in Q1 2014

Ken Fisher 18,266 sh (+796.27%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Sold Out 0.99%$223.85 - $295.88 $ 306.218%0
Vanguard Health Care Fund 2013-12-31 Reduce -39.09%0.47%$223.85 - $295.88 $ 306.218%884000
Ray Dalio 2013-12-31 Add 208.67%0.03%$223.85 - $295.88 $ 306.218%19057
John Hussman 2013-09-30 Add 50%0.33%$206.53 - $248.13 $ 306.237%75000
Ray Dalio 2013-09-30 Reduce -41.27%0.01%$206.53 - $248.13 $ 306.237%6174
Mario Gabelli 2013-09-30 Add 81.87%$206.53 - $248.13 $ 306.237%3310
John Hussman 2013-06-30 Reduce -80.62%1.45%$192.77 - $240.86 $ 306.243%50000
Frank Sands 2013-06-30 Add 27.6%0.71%$192.77 - $240.86 $ 306.243%4565921
PRIMECAP Management 2013-06-30 Reduce -5%0.28%$192.77 - $240.86 $ 306.243%18246809
Ray Dalio 2013-06-30 Reduce -78.85%0.07%$192.77 - $240.86 $ 306.243%10512
Mario Gabelli 2013-06-30 Reduce -25.1%$192.77 - $240.86 $ 306.243%1820
Frank Sands 2013-03-31 New Buy2.4%$142.82 - $192.618 $ 306.290%3578308
John Hussman 2013-03-31 Reduce -48.4%0.92%$142.82 - $192.618 $ 306.290%258000
Ray Dalio 2013-03-31 Add 172.25%0.06%$142.82 - $192.618 $ 306.290%49712
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Idec Inc

Ken Fisher's Top Increases of the First Quarter
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy first quarter. Fisher purchased a total of 57 new stocks. His first quarter portfolio holds 541 stocks and is valued at over $44.34 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 39.10
BIIB's P/E(ttm) is ranked higher than
57% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. BIIB: 39.10 )
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74   Max: 120.59
Current: 39.1

11.74
120.59
P/B 8.40
BIIB's P/B is ranked lower than
56% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BIIB: 8.40 )
BIIB' s 10-Year P/B Range
Min: 1.59   Max: 9.51
Current: 8.4

1.59
9.51
P/S 10.53
BIIB's P/S is ranked higher than
55% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. BIIB: 10.53 )
BIIB' s 10-Year P/S Range
Min: 2.8   Max: 20.67
Current: 10.53

2.8
20.67
EV-to-EBIT 27.80
BIIB's EV-to-EBIT is ranked lower than
56% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. BIIB: 27.80 )
BIIB' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 79.3
Current: 27.8

8.3
79.3
PEG 1.90
BIIB's PEG is ranked higher than
69% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BIIB: 1.90 )
BIIB' s 10-Year PEG Range
Min: 0.12   Max: 2.54
Current: 1.9

0.12
2.54
Shiller P/E 61.80
BIIB's Shiller P/E is ranked higher than
50% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. BIIB: 61.80 )
BIIB' s 10-Year Shiller P/E Range
Min: 23.8   Max: 114.6
Current: 61.8

23.8
114.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 24.80
BIIB's Price/Tangible Book is ranked lower than
85% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. BIIB: 24.80 )
BIIB' s 10-Year Price/Tangible Book Range
Min: 0.22   Max: 25.38
Current: 24.8

0.22
25.38
Price/DCF (Projected) 3.50
BIIB's Price/DCF (Projected) is ranked higher than
54% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. BIIB: 3.50 )
BIIB' s 10-Year Price/DCF (Projected) Range
Min: 1.17   Max: 25.99
Current: 3.5

1.17
25.99
Price/Median PS Value 1.40
BIIB's Price/Median PS Value is ranked higher than
54% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BIIB: 1.40 )
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 4.22
Current: 1.4

0.04
4.22
Price/Peter Lynch Fair Value 2.20
BIIB's Price/Peter Lynch Fair Value is ranked higher than
58% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BIIB: 2.20 )
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.64   Max: 20.5
Current: 2.2

0.64
20.5
Price/Graham Number 6.50
BIIB's Price/Graham Number is ranked lower than
72% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. BIIB: 6.50 )
BIIB' s 10-Year Price/Graham Number Range
Min: 1.75   Max: 18.82
Current: 6.5

1.75
18.82
Earnings Yield (Greenblatt) 3.60
BIIB's Earnings Yield (Greenblatt) is ranked higher than
55% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BIIB: 3.60 )
BIIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 12
Current: 3.6

1.3
12
Forward Rate of Return (Yacktman) 18.42
BIIB's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. BIIB: 18.42 )
BIIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.2   Max: 270.7
Current: 18.42

-0.2
270.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany
Biogen Idec Inc., was formed as a California corporation in 1985 and became a Delaware corporation in 1997. In 2003, the Company acquired Biogen, Inc. and changed its corporate name from IDEC Pharmaceuticals Corporation to Biogen Idec Inc. The Company is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. The Company also collaborates on the development and commercialization of RITUXAN and anti-CD20 product candidates for the treatment of non-Hodgkin's lymphoma and other conditions. The Company's marketed products include AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. AVONEX is one of the prescribed treatments in the world for relapsing forms of MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. TYSABRI has advanced the treatment of MS patients with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. FUMADERM is approved for the treatment of severe psoriasis in Germany. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care 'fraud and abuse,' including anti-kickback laws and false claims laws.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide